Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Lotronex Risk Management Plan Should Not Be Altered, Cmte. Says

Executive Summary

GlaxoSmithKline's risk management program for Lotronex should not be altered until further data is collected, FDA's Drug Safety & Risk Management Advisory Committee recommended May 5

You may also be interested in...



Wellbutrin Offers Optimistic Case Study For Tysabri

The regulatory and commercial history of the antidepressant brand Wellbutrin may be one precedent for Biogen Idec and Elan to emulate in attempting to salvage the multiple sclerosis therapy Tysabri

Wellbutrin Offers Optimistic Case Study For Tysabri

The regulatory and commercial history of the antidepressant brand Wellbutrin may be one precedent for Biogen Idec and Elan to emulate in attempting to salvage the multiple sclerosis therapy Tysabri

Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs

Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies

Related Content

UsernamePublicRestriction

Register

PS043928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel